Chemours (NYSE:CC) Upgraded at Barclays

Barclays upgraded shares of Chemours (NYSE:CC) to a hold rating in a report issued on Monday morning,Zacks reports.

CC has been the topic of several other reports. Mizuho reiterated a “neutral” rating and set a $15.00 price target (down from $18.00) on shares of Chemours in a research report on Wednesday. JPMorgan Chase & Co. cut their price objective on shares of Chemours from $22.00 to $15.00 and set a “neutral” rating for the company in a research report on Thursday, August 13th. Zacks Research raised shares of Chemours from a “strong sell” rating to a “hold” rating in a research note on Thursday, September 10th. Weiss Ratings cut shares of Chemours from a “sell (d)” rating to a “sell (d-)” rating in a research note on Thursday, August 6th. Finally, The Goldman Sachs Group reaffirmed a “neutral” rating and set a $16.00 target price on shares of Chemours in a report on Friday, October 9th. Three analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Chemours currently has an average rating of “Hold” and a consensus target price of $18.09.

Chemours Price Performance

Shares of NYSE CC opened at $12.81 on Monday. The company has a debt-to-equity ratio of 18.98, a quick ratio of 0.88 and a current ratio of 1.66. Chemours has a fifty-two week low of $10.44 and a fifty-two week high of $28.67. The stock has a market cap of $1.93 billion, a PE ratio of -6.71 and a beta of 1.41. The stock has a fifty day moving average of $14.79 and a 200-day moving average of $18.97.

Chemours (NYSE:CC) last issued its quarterly earnings data on Tuesday, August 4th. The specialty chemicals company reported $0.42 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.49 by ($0.07). Chemours had a positive return on equity of 60.64% and a negative net margin of 5.00%. The company had revenue of $1.59 billion for the quarter, compared to analysts’ expectations of $1.65 billion. During the same period last year, the company posted ($2.54) EPS. The business’s revenue for the quarter was down 1.5% on a year-over-year basis. Equities research analysts anticipate that Chemours will post 0.84 earnings per share for the current year.

Chemours Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 15th. Stockholders of record on Friday, August 14th were issued a $0.0875 dividend. The ex-dividend date of this dividend was Friday, August 14th. This represents a $0.35 dividend on an annualized basis and a dividend yield of 2.7%. Chemours’s dividend payout ratio is presently -18.32%.

Insider Activity

In related news, CFO Shane Hostetter acquired 3,350 shares of the company’s stock in a transaction dated Thursday, August 6th. The stock was bought at an average cost of $14.94 per share, with a total value of $50,049.00. Following the acquisition, the chief financial officer owned 102,698 shares of the company’s stock, valued at approximately $1,534,308.12. The trade was a 3.37% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Denise Dignam acquired 3,378 shares of the company’s stock in a transaction dated Tuesday, August 11th. The shares were bought at an average cost of $14.95 per share, with a total value of $50,501.10. Following the completion of the acquisition, the chief executive officer directly owned 339,916 shares in the company, valued at $5,081,744.20. The trade was a 1.00% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders have purchased 8,663 shares of company stock worth $130,601. 0.85% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Chemours

Hedge funds have recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company purchased a new stake in Chemours in the second quarter worth approximately $1,522,000. Deutsche Bank AG purchased a new position in shares of Chemours during the second quarter worth approximately $3,291,000. BlackRock Inc. purchased a new position in shares of Chemours during the second quarter worth approximately $477,769,000. Old West Investment Management LLC purchased a new position in shares of Chemours during the second quarter worth approximately $7,152,000. Finally, Jefferies Financial Group Inc. purchased a new position in shares of Chemours during the second quarter worth approximately $15,996,000. Institutional investors own 76.26% of the company’s stock.

Key Stories Impacting Chemours

Here are the key news stories impacting Chemours this week:

• Positive Sentiment: BMO Capital reaffirmed its Buy rating, indicating that some analysts still see recovery potential in Chemours despite the recent weakness. BMO Capital reaffirms Buy rating
• Neutral Sentiment: Barclays initiated coverage at Equal Weight, while Mizuho maintained a Neutral rating but reduced its price target to $15 from $18. The new target still implies potential upside from recent trading levels, but the cut signals more cautious expectations. Mizuho downgrades Chemours
• Negative Sentiment: RBC Capital downgraded Chemours to Sector Perform from Outperform and cut its price target to $14 from $22, citing persistent TiO₂ weakness, soft chemical demand and potential headwinds in the Thermal & Specialized Solutions segment through year-end. RBC downgrades Chemours
• Negative Sentiment: Several law firms announced or promoted a securities-fraud class action filed against Chemours and certain officers. The case covers investors who purchased shares from February 20 through August 4, 2026, and alleges investors were harmed by disclosures concerning Opteon refrigerant aftermarket demand. The lead-plaintiff deadline is December 7, 2026. Although the allegations have not been proven, the litigation creates legal, financial and reputational risks. Chemours securities-fraud class action

About Chemours

The Chemours Company (NYSE: CC) is a global chemical company that develops, manufactures and distributes specialty chemical products used in a range of industrial and consumer applications. Its portfolio serves markets including coatings, plastics, automotive, refrigeration and air conditioning, electronics, telecommunications, energy, healthcare and general manufacturing.

Chemours operates through three primary business segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials.